Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Taiwan-Based Bora Pharmaceuticals Expands Baltimore, Maryland Operations

11/13/2025
Taiwan-based pharmaceutical manufacturer Bora Pharmaceuticals plans to expand its operations in Baltimore, Maryland.

The $15 million project will include the installation of a new automated vial, syringe, and cartridge line at the company’s existing facility.

“Bora is more frequently seeing demand for drug product fill and finish of potent drug candidates and approved treatments, as well as for rare and orphan diseases,” said J.D. Mowery, president of Bora’s CDMO division. “The addition of a precision small-scale isolator line adds to our overall capacity, and working in concert with our existing large-scale lines, increases our flexibility and scalability.”

To support the project the company has submitted a Notice of Intent to utilize the state’s One Maryland Tax Credit, which provides an income tax credit to businesses that invest in an economic development project in specific jurisdictions and create a minimum number of qualified jobs.

“As one of the leading states for the life sciences, Maryland is excited to have Bora Pharmaceuticals as part of our community and proud to support its reinvestment in Baltimore,” noted Maryland Commerce Secretary Harry Coker, Jr. “Maryland and Taiwan are also natural partners—our friendship goes back many years—so we are thrilled to have another successful Taiwanese company making an impact locally and around the world.”

Bora Pharmaceuticals is a contract development and manufacturing organization (CDMO) that offers services from drug development and clinical to commercial manufacturing and packaging for pharmaceutical products. The company specializes in various complex drug forms, including oral solids, liquids, semi-solids, biologics, and sterile injectables.

Exclusive Research